Faropair CV Tablet contains a combination of Faropenem (200mg) and Clavulanic Acid (125mg), designed to enhance the effectiveness of the antibiotic therapy. Faropenem is a broad-spectrum antibiotic from the penem class that works by inhibiting bacterial cell wall synthesis, causing bacterial cell death. Clavulanic Acid is a beta-lactamase inhibitor that prevents certain bacteria from becoming resistant to Faropenem by inhibiting the enzymes that would normally degrade the antibiotic.
This combination makes Farovax CV Tablet highly effective against a wide range of bacterial infections, including those caused by resistant bacteria. The combination therapy is particularly useful for treating infections that may involve beta-lactamase-producing organisms, which can render some antibiotics ineffective. Farovax CV Tablet is often used for treating respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other systemic bacterial infections.
The tablet is typically prescribed for patients with infections that are resistant to other first-line antibiotics, as well as for complicated or mixed infections where multiple bacterial species are involved. The combination of Faropenem and Clavulanic Acid allows it to be effective against a broader spectrum of bacterial pathogens.
Patients should take Farovax CV Tablet as directed by their healthcare provider, typically with or without food. The full course of therapy should be completed to prevent the development of antibiotic resistance and to ensure the infection is fully treated. It is crucial to avoid skipping doses, as this can reduce the effectiveness of the treatment.